Verastem to present VS-7375 TARGET-D data on Oct 14
Verastem says it will unveil initial efficacy and updated safety data for oral KRAS G12D inhibitor VS-7375 from the TARGET-D trial across pancreatic, lung and colorectal cancers on Oct 14, 2026; BTIG reiterates a $18.00 price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.